Bringing innovation and technology to the patient-care journey
As part of Kyowa Kirin’s Commitment to Life, we have a focus in Australia on rare diseases and their treatments. We want to become a trusted partner to patients, carers, healthcare professionals and other stakeholders in this arena.
Embarking on a journey that is less visited
Kyowa Kirin aims to deliver innovative technology in Australia’s rare disease space. We work with our global team to bring in pharmaceutical candidates, using state-of-the-art technologies for the following treatment areas.
As a company rich in culture and diversity, we welcome and are flexible to strategic collaborations and partnerships with pharmaceutical firms, biotechnology companies, and academia partners in rare disease.
Cutaneous T-cell Lymphoma (CTCL)
One area of such focus is Cutaneous T-cell Lymphoma (CTCL), an ongoing unmet need. This haematological cancer initially affects the skin but then can also involve the blood, lymph nodes, and other internal organs.
Ref: Australian Clinical Practice Statement: MYCOSIS FUNGOIDES AND SEZARY SYNDROME. July 2020
X-linked hypophosphataemia (XLH)
Another area is X-linked hypophosphataemia (XLH), a rare genetic disorder which causes phosphate wasting, and affects children and adults. The progressive and compounding symptoms of XLH lead to skeletal defects, muscular dysfunction, and dental abnormalities.
Ref: Haffner et al. Nat Rev Nephrol. 2019 Jul;15(7):435-455
Making the journey count
Kyowa Kirin is a Japan-based Global Specialty Pharmaceutical Company, contributing to human health and well-being worldwide through innovative drug discovery and global commercialisation, driven by state-of-the-art antibody technologies, in the core therapeutic areas of Nephrology, Oncology, Immunology & Allergy, and Central Nervous System.